Tuesday, October 26, 2010

Cancer drugs RIPed in 2010

Four of the top ten Phase III failures of 2010 that were listed at FierceBiotech on Oct 21st are cancer drugs, and that's a big number!

ASA404 (vadimezan, formerly known as AS1404, DMXAA; Antisoma/Novartis) failed in a non-small cell lung cancer trial, ATTRACT-2.   It is a small molecule Vascular Disrupting Agent (VDA) targeting established blood vessels in tumor. (read here and here
NOV-002 (Novelos Therapeutics) also failed a non-small cell lung cancer trial.  It is a proprietary formulation of oxidized glutathione, or “GSSG” in a 1000:1 ratio of GSSG with cisplatin. 
Zibotentan (ZD4054, AstraZeneca) failed in prostate cancer.  It is endothelin pathway blocker
Recentin (cediranib, AstraZeneca) for colon cancer also failed in a head-to-head study with Avastin.  Recentin is a VEGFR tyrosine kinase inhibitor.
NV1FGF (Sanofi-Aventis and Vical), a proangiogenic agent, also did not deliver in TAMARIS trial.  It did not prove superior to placebo in preventing death and disease from critical limb ischemia.  It is a pCOR plasmid-based angiogenic gene therapy delivering FGF1 (read more).

Four of the five drugs listed above were targeting angiogenic signaling.  Cancer remains a tough nut to crack but angiogenic pathways remain the bull's eye.  As is often the case, these drugs may reappear in another trial in 2011.

No comments:

Post a Comment